Skip to main content

Security report for biogen.lv

Biogen Latvia SIA · Healthcare · Latvia

Low risk. 2 critical or high findings in Email security and SSL/TLS.

Security score

77/100

Risk levelLow

0–100, higher is better. How it is calculated

Biogen Latvia SIA operates as a regional branch of the global biotechnology leader Biogen Inc., focusing on innovative therapies for neurological and rare diseases. The website reflects a professional corporate presence with clear branding, comprehensive content about their business focus, and a user-friendly interface optimized for mobile devices. The technical infrastructure leverages Adobe Experience Manager CMS, modern JavaScript libraries, and robust cookie consent management via Cookiebot, ensuring compliance with GDPR and enhancing user privacy. Security posture is strong with HTTPS enforced and secure cookie practices, though there is room for improvement in publishing explicit security policies and headers. Overall, the site demonstrates a mature digital presence aligned with industry standards and regulatory requirements.

Scanned

NIS2 and GDPR posture

GDPR outside view
83/ 100 · Low
Checks completed
7of 7

NIS2 Art. 21(2)

  1. (a) Risk analysis and security policies: Not visible from outside
  2. (b) Incident handling: One indicator
  3. (c) Business continuity, backups and crisis management: Not visible from outside
  4. (d) Supply chain security: Not visible from outside
  5. (e) Secure acquisition, development and maintenance, including vulnerability handling: Partly checked
  6. (f) Assessing the effectiveness of security measures: Not visible from outside
  7. (g) Cyber hygiene and security training: Not visible from outside
  8. (h) Cryptography and encryption: Partly checked
  9. (i) HR security, access control and asset management: One indicator
  10. (j) Multi-factor authentication and secured communications: Not visible from outside

This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.

GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.

Priority findings

2 findings rated critical or high. Fix these first.

  1. Email security

    SPF, DKIM and DMARC stop others sending email that looks like it comes from your domain, a common route to phishing and invoice fraud.

    • Critical

      No email authentication configured

      Domain is vulnerable to email spoofing

      What to do: Implement SPF, DKIM, and DMARC immediately

  2. SSL/TLS

    TLS encrypts the connection and proves the site is really yours. Weak or expiring certificates trigger browser warnings and put traffic at risk.

    • High

      Weak Protocols Supported

      Server supports weak protocols: TLSv1.1

      What to do: Disable TLS 1.0, TLS 1.1, and all SSL versions

      • CWE-327
      • OWASP A04:2025
      • ASVS V12.1.1

Need hands-on remediation? Email guard@offseq.com

Keep watching biogen.lv

This scan found 20 issues across 6 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.

Daily monitoring

Recommended

€25per month

  • TLS certificates and expiry
  • DNS records
  • SPF, DKIM and DMARC
  • Security headers
  • GDPR and NIS2 posture
  • Exposed services
  • Third-party trackers
  • Security score drift

Email alerts on material changes and an exportable JSON history of every change.

Billed monthly to your card. Cancel anytime. The full timeline opens with your unlock code.

Full report

€39.90one-time

  • The complete analysis as a PDF you can cite
  • Email delivery with an unlock code
  • Lifetime access to this report

Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.

Results by check

Each check with its score, findings and the evidence it collected.

How this score is calculated

The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.

Counted in this score

SSL/TLS
62
Security headers
95
Email security
60
DNS health
60
Network security
100
GDPR outside view
83
Average
77

Not counted

  • NIS2 outside view: Re-weights evidence from the TLS, email, DNS, network and hygiene checks, so counting it would count that evidence twice. Shown on its own.
  • OffSeq Observations: An AI reading of the site, useful context but not reproducible evidence. Shown on its own.

Findings that cap the score at 49

Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.

  • The certificate is not trusted by browsers
  • The website is not served over HTTPS
  • A database, remote desktop, file-sharing or Telnet service is reachable from the internet
  • The page loads a script from a compromised source
  • The domain registration has expired
  • SPF authorises every server to send mail as the domain

Partial scans

When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.

Risk levels

  • Critical0–25
  • High26–49
  • Medium50–75
  • Low76–100

Technical appendix

Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.

Business context

Business profile

Biogen Latvia is positioned as a key player in the biotechnology healthcare sector within Latvia, serving patients, healthcare professionals, and stakeholders. The company benefits from its global parentage, leveraging advanced research and development capabilities. The business model centers on pharmaceutical innovation and therapy commercialization, with a strong emphasis on neurological diseases. The website supports this positioning with detailed disease area information, career opportunities, and corporate responsibility content. The presence of multiple regional sister sites indicates a well-structured international footprint. The company maintains a transparent and compliant approach to data privacy and user consent, reflecting a customer-centric and regulatory-aware business strategy.

Security posture

The website employs HTTPS with strong SSL configuration and uses HttpOnly cookies to enhance security. Cookie consent is managed through Cookiebot, providing granular user control and GDPR compliance. However, the absence of explicit security headers such as Content-Security-Policy and X-Frame-Options represents an area for enhancement. No public security policy or incident response contact is available, which could limit transparency in case of security incidents. No vulnerabilities or exposed sensitive data were detected in the analysis. Overall, the security posture is solid but could benefit from additional transparency and technical hardening.

Recommendations

  1. Publish a dedicated security policy page outlining security practices and incident response procedures.
  2. Implement and enforce security headers like Content-Security-Policy, X-Frame-Options, and X-Content-Type-Options.
  3. Add a security.txt file to facilitate responsible vulnerability disclosure.
  4. Enhance accessibility features to meet higher compliance standards.
  5. Regularly review and update third-party scripts and libraries to mitigate potential vulnerabilities.
Site observations

Automated reading of the public site. Ratings are indicative.

Business

Company
Biogen Latvia SIA
Description
Biogen is one of the largest global biotechnology companies, pioneering science and innovation for the treatment of complex and serious diseases. It develops potential therapies in neurology, neuropsychiatry, specialized immunology, and rare diseases, focusing on serving humanity through science and promoting a healthier, sustainable, and fairer world.
Key services
Development of therapies for multiple sclerosis, Treatment for spinal muscular atrophy, Alzheimer's disease treatment innovations
Content quality
good
Branding
consistent

Technology

Stack
Adobe Helix RUM, Cookiebot, Google Tag Manager, jQuery 3.6.4, Video.js
Frameworks
Adobe Experience Manager (AEM)
Platforms
Web
Performance
moderate
Mobile
good
Accessibility
basic
SEO
good

Security

Observed score
85/100
Good practices seen
  • HTTPS enforced
  • Cookie consent management implemented
  • HttpOnly cookies used
  • Load balancing cookies for server optimization

Analytics and tracking

Services
Google Analytics
Tracking level
moderate
Privacy practices
good

Advertising

Tracking pixels
Cookiebot session tracker
Transparency
good

Site quality

Design
good
User experience
good
Content relevance
good
Navigation
good
Professionalism
good
Trustworthiness
high

Key observations

  1. Website is fully accessible with no blocking or WAF challenges.
  2. Comprehensive cookie consent mechanism implemented via Cookiebot.
  3. Clear corporate branding and consistent navigation structure.
  4. No direct company emails or phone numbers found on the homepage; contact form is primary contact method.
  5. Use of modern web technologies and Adobe Experience Manager CMS.
  6. Social media presence on major platforms enhances trust and engagement.
  7. No explicit security policy or incident response information publicly available.
  8. No vulnerability disclosure or security.txt file detected.
Technical notes

Notes

The website is built on Adobe Experience Manager, a robust enterprise CMS platform, ensuring scalability and content management efficiency. It uses modern JavaScript libraries including jQuery 3.6.4 and Adobe Helix RUM for performance monitoring. Cookiebot is integrated for consent management, reflecting strong privacy compliance. The site includes multimedia content with Video.js for video playback. Performance is moderate with room for optimization, especially in mobile responsiveness and accessibility. SEO practices are well implemented with proper meta tags and Open Graph data. Hosting appears to be managed via Biogen's CDN infrastructure, ensuring reliable content delivery. Overall, the technical stack is modern and well-suited for a corporate healthcare website.
Standards and sources

Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.

Retrieved 2026-10-25

Reviews of this site

Share your experience with biogen.lv. Every review is verified by email and published after moderation.

Overall rating
Select a rating
4000 characters remaining

We’ll email you to confirm your review and keep your details private.

Community rating

No published reviews yet. Be the first to review biogen.lv.

Feedback on this report

Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.

Overall report quality
Select a rating
2000 characters remaining

We only use your feedback to improve Guard reports. Contact details are never shared.